Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomvastomig and Tobemstomig vs Nivolumab in Advanced Esophageal Squamous Cell Carcinoma
NCT04785820Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of lomvastomig and tobemstomig in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Roche. Primary endpoint: Overall Survival at 38.7 months. Started Jun 2021; status: completed.
02
Drugs
lomvastomigtobemstomig
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04785820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785820.